Inhibikase TherapeuticsIKT -1.06%36 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates IKT with a GF Score™ of 36/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Inhibikase Therapeutics ranks worse than 105820% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Inhibikase Therapeutics EBITDA Margin % Related Terms
Inhibikase Therapeutics EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IKT vs NKTX, CAMP, NERV: EBITDA Margin % Comparison
For the Biotechnology subindustry, Inhibikase Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibikase Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Inhibikase Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics (IKT) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Inhibikase Therapeutics and its competitors. According to the industry distribution chart, Inhibikase Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is Inhibikase Therapeutics' EBITDA Margin % too high?
Inhibikase Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Inhibikase Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Inhibikase Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' EBITDA Margin % compare to NKTX and CAMP?
According to the Biotechnology industry distribution chart, Inhibikase Therapeutics ranks #999999 out of 945 companies for EBITDA Margin %. This places Inhibikase Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Inhibikase Therapeutics and its competitors. Inhibikase Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Inhibikase Therapeutics' overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
36GF Score
Get the complete analysis for IKT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IKT has been successfully added to your 
